Oncolytics receives Canadian patent for cancer treatment
Matt Coffey, chief scientific officer of Oncolytics, said: “This is a broad patent that expands our coverage in Canada in the area of cancers with inactivated PKR.”
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
The research showed that Sterilox Solution completely inactivated the H5N1 test strain and passed the US Environmental Protection Agency’s recommended hard-surface disinfection test, which requires two-minutes contact time.